Telo Genomics Corp AI Stock Analysis
Want to see TSE:TELO full AI Analyst Report?
Telo Genomics Corp (TELO) AI Stock Analysis
Telo Genomics Corp
(TSXV:TELO)
The overall score is critically low, driven primarily by a fundamentally broken financial profile with zero revenue, negative equity, and ongoing cash burn. Technical indicators show weak momentum and oversold conditions, while the negative P/E ratio confirms the lack of earnings power. The company faces severe liquidity and solvency risks without a clear path to profitability.
Telo Genomics Corp (TELO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 5.52M
- Dividend Yield
- ―
- Average Volume (3M)
- 94.06K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 1.18
- Revenue Growth
- ―
- EPS Growth
- 25.57%
- Country
- Canada
- Employees
- 8
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Telo Genomics Corp Business Overview & Revenue Model
Company Description
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health con...
Telo Genomics Corp Financial Statement Overview
Summary
The company is pre-revenue with zero income, deeply negative earnings, and a balance sheet that has flipped to negative equity (-$1.58M) with new debt. Cash burn is high, and the asset base has eroded to just $0.6M, indicating severe financial distress.
Income Statement
1Very NegativeBalance Sheet
5Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Jun 2026 | Sep 2025 | Sep 2024 | Jun 2022 | Sep 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -86.56K | -86.56K | -14.45K | -39.54K | -33.11K | -62.23K |
| EBITDA | -2.10M | -2.10M | -2.69M | -2.67M | -2.78M | -1.01M |
| Net Income | -2.31M | -2.31M | -2.72M | -2.71M | -2.82M | -1.07M |
Balance Sheet | ||||||
| Total Assets | 599.90K | 599.90K | 911.30K | 965.64K | 2.93M | 3.84M |
| Cash, Cash Equivalents and Short-Term Investments | 338.32K | 338.32K | 789.29K | 796.02K | 2.67M | 3.64M |
| Total Debt | 1.44M | 1.44M | 0 | 0 | 32.50K | 40.00K |
| Total Liabilities | 2.18M | 2.18M | 396.32K | 375.59K | 312.87K | 153.66K |
| Stockholders Equity | -1.58M | -1.58M | 514.98K | 590.06K | 2.61M | 3.69M |
Cash Flow | ||||||
| Free Cash Flow | -1.61M | -1.61M | -2.33M | -2.46M | -2.70M | -1.11M |
| Operating Cash Flow | -1.59M | -1.59M | -2.33M | -2.46M | -2.63M | -1.10M |
| Investing Cash Flow | -18.75K | -18.75K | -3,250 | -5,115 | -69.06K | -9,310 |
| Financing Cash Flow | 1.16M | 1.16M | 2.33M | 587.05K | 2.68M | 3.83M |
Telo Genomics Corp Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 36.18 is Neutral, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TELO.
Telo Genomics Corp Peers Comparison
Overall Rating
- TSE:TELO41Neutral
TSE:KNE40Underperform
TSE:BUX37Underperform
TSE:SONA37Underperform
TSE:AVCR26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:TELO | 41Neutral | CAD 4.51M | -1.96 | 295.03% | ― | ― | 25.57% |
| TSE:KNE | 40Underperform | CAD 6.15M | -2.05 | 273.53% | ― | ― | ― |
| TSE:BUX | 37Underperform | CAD 44.72M | -31.11 | -250.77% | ― | -82.05% | 23.73% |
| TSE:SONA | 37Underperform | CAD 30.70M | -12.62 | 448.05% | ― | ― | 24.65% |
| TSE:AVCR | 26Underperform | CAD 5.69M | -2.56 | -241.33% | ― | -93.73% | -25.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:TELO | Telo Genomics | 0.04 | -0.04 | -43.75% | |
| TSE:BUX | BioMark Diagnostics | 0.42 | 0.07 | 20.00% | |
| TSE:SZLS.H | Stagezero Life Sciences | 0.04 | 0.00 | 0.00% | |
| TSE:KNE | Kane Biotech | 0.03 | -0.01 | -25.00% | |
| TSE:SONA | Sona Nanotech, Inc | 0.27 | -0.24 | -47.06% | |
| TSE:AVCR | Avricore Health | 0.04 | -0.01 | -18.18% |
Telo Genomics Corp Corporate Events
Telo Genomics Secures $250,000 Term Loan for Operations
PositiveTelo Genomics is a biotechnology company developing diagnostic and prognostic tests based on three-dimensional telomere analysis. Its platform targets liquid biopsy applications in oncology and neurological diseases, serving clinicians, pathologists,...
Telo Genomics Expands Global Studies to Validate Blood-Based Myeloma MRD Test
PositiveTelo Genomics Corp. is a Vancouver-based diagnostics company developing diagnostic and prognostic tests that use three-dimensional analysis of telomeres, the ends of chromosomes. Its flagship liquid-biopsy assay, TELO-MRD, targets measurable residual...
Telo Genomics’ Blood-Based TELO-MRD Shows Strong MRD Detection in Multiple Myeloma Comparisons
PositiveTelo Genomics has reported new clinical research results from its TELO-MRD program in multiple myeloma, comparing blood-based TELO enumeration of circulating plasma cells with bone-marrow Adaptive clonoSEQ next-generation sequencing. The company’s li...
Telo Genomics’ Blood-Based Myeloma Assay Outperforms Bone-Marrow MRD Test in Study
PositiveTelo Genomics reported clinical research results showing that its TeloView-based TELO-MRD blood assay detected residual multiple myeloma cells in a substantially higher proportion of matched samples than standard bone-marrow EuroFlow next-generation...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026